Beckman Coulter Life Sciences’ Post

Finally small molecules are doing big…. AZ is exploring the potential to use small molecule drugs to target RNA. Small molecule drugs have been the mainstay of the pharmaceutical industry for nearly a century. Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics: most can be administered orally and they can pass through cell membranes to reach intracellular targets. They can also be designed to engage biological targets by various modes of action and their distribution can further be tailored, for example to allow for systemic exposure with or without brain penetration. Modulating biological disease driving pathways at the RNA level opens up new opportunities for previous undruggable targets

Gilead Sciences and Genesis Therapeutics Partner on AI-Driven Drug Discovery - HIT Consultant Summary: Gilead Sciences and Genesis Therapeutics have joined forces to leverage AI in drug discovery, aiming to revolutionize the pharmaceutical industry. The partnership focuses on accelerating the development of innovative treatments through advanced technology and data analysis. Key areas of collaboration include AI algorithms, machine learning models, and predictive analytics to enhance drug discovery processes. This strategic alliance between Gilead and Genesis signifies a significant step towards integrating AI into healthcare research and development, paving the way for groundbreaking advancements in medicine. #Gilead #Genesis #AI #DrugDiscovery #HealthcareIT Headings: 1. Introduction to Gilead Sciences and Genesis Therapeutics Partnership #Gilead #Genesis #Partnership 2. Leveraging AI in Drug Discovery #AI ai.mediformatica.com #gilead #collaboration #platform #aiplatform #drugdevelopment #advanced #biopharmaceutical #drugdiscovery #edge #partnership #strategic #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3XlCXlW)

Two innovative NMR experiments have been developed to enhance the sensitivity and speed of biologic drug screening, facilitating the analysis and characterization of biologics during drug discovery. These methods allow for rapid assessment of structural stability and behavior, even at low concentrations. Their effectiveness is demonstrated through various examples, including therapeutic proteins and stressed samples. Learn more: https://lnkd.in/dVeBTBVf #NMR #Pharma #DrugScreening

Isomorphic Labs has announced collaborations with pharmaceutical giants Eli Lilly and Novartis for AI-driven drug discovery. The partnerships aim to leverage Isomorphic Labs' expertise in artificial intelligence to enhance the drug discovery process. The article provides insights into the potential impact of these collaborations on advancing innovative drug development through the integration of cutting-edge technologies. #machinelearning #artificialintelligence #drugdiscovery #pharmaceutical #drugdevelopment #smallmolecule #computationalchemistry #structuralbiology

Small molecules are very agile. With the recent rush for biological treatments, people seem to forget the fundamentals: When the system or a product is more complex (biological drug), it has many more places to break. The probability grows exponentially. It is simple math. So, don't over-engineer if you can. This is a good example: a small molecule for a cell surface receptor (could have been a biological one). 200 million in these market conditions? #smallmolecules #biologicals #pharmaceuticals https://lnkd.in/gpukQiMC

#Clinical_Stage_Biotechnology Market Share Charges Ahead with Huge Growth 2023-2032 https://lnkd.in/dtEG_mxy #Clinical stage biotechnology refers to a #phase in the development of biotechnological #products, particularly #therapeutic drugs or interventions, where the focus #shifts from preclinical #research and testing to human clinical #trials. These are designed to assess the #safety, efficacy, and optimal #dosage of the biotechnological #product in humans. Minoryx Therapeutics Inhibrx, Inc. NovaBiotics Ltd Radiomedix, Inc. Artax Biopharma Inc Ribon Therapeutics Brickell Travel Management Coave Therapeutics Edesa Biotech, Inc. CellCentric LimmaTech Biologics AG Adaptive Phage Therapeutics Intrainz #technologies #marketgrowth #innovationmanagement #clinical #biotechnology #therapeutic #drugs #research

Unlocking the Future of Drug Discovery: Challenges & Fragment-Based Approaches! 🧬💡 I’ve just completed a Module 4 on Fragment-Based Drug Discovery (FBDD) and wanted to share some crucial insights into this innovative approach in pharmaceutical R&D. 🚀💊 🔹 Challenges in Drug Discovery: Small molecule drug discovery often faces pitfalls, but FBDD offers a promising strategy to overcome these hurdles by targeting proteins like protein kinases with high specificity. 🔹 Fragment-Based Drug Design: FBDD focuses on screening small molecular fragments, which are simpler but powerful building blocks for developing potent drugs. This allows for more efficient targeting and optimization of drug candidates at an early stage. 🔹 Lipophilicity Matters! The optimal balance of lipophilicity (cLogP <3) and molecular weight (MW <400) is critical for drug efficacy and selectivity. Too much lipophilicity can lead to off-target effects, but maintaining just the right balance ensures strong, selective binding to targets. 🔹 Preclinical Success: With advanced methods like HT Crystallography, SPR, and in vivo imaging, preclinical studies are able to fine-tune potential drugs, ensuring that only the best candidates make it through the rigorous development process. 🔹 Efficiency in Drug Development: In FBDD, fragment libraries of 1000s of molecules help to rapidly identify leads, allowing researchers to streamline drug design for quicker development. This module highlighted how fragment-based approaches are changing the landscape of drug discovery, providing faster and more selective pathways to new treatments. Onward to the next phase of learning! 💼💊 #DrugDiscovery #FBDD #Pharmaceuticals #PreclinicalStudies #ProteinKinases #Biotech #Lipophilicity #PharmaInnovation #SustainableChemistry

Pharmaceutical giant AstraZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn. ℹ Read the full article here: https://lnkd.in/emSp8Vaa #europeanbiotechnology #biotechnology #biotechnews #biotechfinancing #biotech #biotechfinancing

We’ve generated a lot of interest in antibody drug conjugate (ADC) linker design from our feature on Fierce Pharma. If you work on designing ADCs, our experts can greatly increase your chances of success. Check out the editorial below and let us know how we can support your ADC design journey. https://bit.ly/4auHIyK #ADC #BioconjugateTherapeutics #VectorLaboratories

I have completed a course in Drug discovery... Basically drug discovery is the process of identifying new medications for the treatment of diseases. It typically involves several stages, including target identification, lead compound discovery, preclinical testing, clinical trials, and regulatory approval. Scientists use various techniques such as high-throughput screening, computer-aided drug design, and molecular modeling to identify potential drug candidates. Once a promising compound is found, it undergoes rigorous testing to ensure its safety and efficacy before it can be prescribed to patients. Drug discovery is a complex and time-consuming process that requires collaboration between scientists, clinicians, and pharmaceutical companies to bring new treatments to market.